-
1
-
-
70949107842
-
Inflammatory bowel disease
-
Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361(21):2066–2078.
-
(2009)
N Engl J Med
, vol.361
, Issue.21
, pp. 2066-2078
-
-
Abraham, C.1
Cho, J.H.2
-
2
-
-
34547176642
-
Unravelling the pathogenesis of inflammatory bowel disease
-
Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448(7152):427–434.
-
(2007)
Nature
, vol.448
, Issue.7152
, pp. 427-434
-
-
Xavier, R.J.1
Podolsky, D.K.2
-
3
-
-
0028899859
-
Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators
-
Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. N Engl J Med. 1995;332(5):292–297.
-
(1995)
N Engl J Med
, vol.332
, Issue.5
, pp. 292-297
-
-
Feagan, B.G.1
Rochon, J.2
Fedorak, R.N.3
-
4
-
-
0018888679
-
Treatment of Crohn’s disease with 6-mercaptopurine. A long-term, randomized, double-blind study
-
Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn’s disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med. 1980;302(18):981–987.
-
(1980)
N Engl J Med
, vol.302
, Issue.18
, pp. 981-987
-
-
Present, D.H.1
Korelitz, B.I.2
Wisch, N.3
Glass, J.L.4
Sachar, D.B.5
Pasternack, B.S.6
-
5
-
-
33750133513
-
Interleukin-12 and Th1 immune response in Crohn’s disease: Pathogenetic relevance and therapeutic implication
-
Peluso I, Pallone F, Monteleone G. Interleukin-12 and Th1 immune response in Crohn’s disease: pathogenetic relevance and therapeutic implication. World J Gastroenterol. 2006;12(35):5606–5610.
-
(2006)
World J Gastroenterol
, vol.12
, Issue.35
, pp. 5606-5610
-
-
Peluso, I.1
Pallone, F.2
Monteleone, G.3
-
6
-
-
77949450368
-
The use of ustekinumab in autoimmune disease
-
Ryan C, Thrash B, Warren RB, Menter A. The use of ustekinumab in autoimmune disease. Expert Opin Biol Ther. 2010;10(4):587–604.
-
(2010)
Expert Opin Biol Ther
, vol.10
, Issue.4
, pp. 587-604
-
-
Ryan, C.1
Thrash, B.2
Warren, R.B.3
Menter, A.4
-
7
-
-
43449111187
-
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
-
Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665–1674.
-
(2008)
Lancet
, vol.371
, Issue.9625
, pp. 1665-1674
-
-
Leonardi, C.L.1
Kimball, A.B.2
Papp, K.A.3
-
8
-
-
43449139402
-
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
-
Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675–1684.
-
(2008)
Lancet
, vol.371
, Issue.9625
, pp. 1675-1684
-
-
Papp, K.A.1
Langley, R.G.2
Lebwohl, M.3
-
9
-
-
84883134297
-
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
-
McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382(9894):780–789.
-
(2013)
Lancet
, vol.382
, Issue.9894
, pp. 780-789
-
-
McInnes, I.B.1
Kavanaugh, A.2
Gottlieb, A.B.3
-
10
-
-
84899991797
-
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
-
Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73(6):990–999.
-
(2014)
Ann Rheum Dis
, vol.73
, Issue.6
, pp. 990-999
-
-
Ritchlin, C.1
Rahman, P.2
Kavanaugh, A.3
-
11
-
-
85080486639
-
-
Stelara® [package insert], Janssen Biotech, IncMarch, Accessed August 9, 2016
-
Stelara® [package insert]. Horsham, PA: Janssen Biotech, Inc.; March 2014. Available from: https://www.stelarainfo.com/pdf/prescribinginformation.pdf. Accessed August 9, 2016.
-
-
-
Horsham, P.A.1
-
12
-
-
8344284998
-
Anti-interleukin-12 antibody for active Crohn’s disease
-
Mannon PJ, Fuss IJ, Mayer L, et al. Anti-interleukin-12 antibody for active Crohn’s disease. N Engl J Med. 2004;351(20):2069–2079.
-
(2004)
N Engl J Med
, vol.351
, Issue.20
, pp. 2069-2079
-
-
Mannon, P.J.1
Fuss, I.J.2
Mayer, L.3
-
13
-
-
84871701834
-
Ustekinumab induction and maintenance therapy in refractory Crohn’s disease
-
Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med. 2012;367(16):1519–1528.
-
(2012)
N Engl J Med
, vol.367
, Issue.16
, pp. 1519-1528
-
-
Sandborn, W.J.1
Gasink, C.2
Gao, L.L.3
-
14
-
-
53049091561
-
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease
-
Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology. 2008;135(4):1130–1141.
-
(2008)
Gastroenterology
, vol.135
, Issue.4
, pp. 1130-1141
-
-
Sandborn, W.J.1
Feagan, B.G.2
Fedorak, R.N.3
-
15
-
-
85080564067
-
-
FDA Approves STELARA® (ustekinumab) for Treatment of Adults with Moderately to Severely Active Crohn’s Disease. Janssen Biotech, Incpress releasePR Newswire, September 26, Accessed October 7, 2016
-
FDA Approves STELARA® (ustekinumab) for Treatment of Adults with Moderately to Severely Active Crohn’s Disease. Janssen Biotech, Inc. [press release]. PR Newswire; 2016 [September 26]. Available from: http://www.prnewswire.com/news-releases/fda-approves-stelara-ustekinumab-for-treatment-of-adults-with-moderately-to-severely-active-crohns-disease-300333868.html. Accessed October 7, 2016.
-
(2016)
-
-
-
16
-
-
0037313578
-
Interleukin-12 and the regulation of innate resistance and adaptive immunity
-
Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3(2):133–146.
-
(2003)
Nat Rev Immunol
, vol.3
, Issue.2
, pp. 133-146
-
-
Trinchieri, G.1
-
17
-
-
0024467154
-
Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes
-
Kobayashi M, Fitz L, Ryan M, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med. 1989;170(3):827–845.
-
(1989)
J Exp Med
, vol.170
, Issue.3
, pp. 827-845
-
-
Kobayashi, M.1
Fitz, L.2
Ryan, M.3
-
18
-
-
0030445948
-
A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits
-
Presky DH, Yang H, Minetti LJ, et al. A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. Proc Natl Acad Sci U S A. 1996;93(24):14002–14007.
-
(1996)
Proc Natl Acad Sci U S A
, vol.93
, Issue.24
, pp. 14002-14007
-
-
Presky, D.H.1
Yang, H.2
Minetti, L.J.3
-
19
-
-
0036604306
-
A receptor for the heterodimeric cytokine IL-23 is composed of IL-12 Rbeta1 and a novel cytokine receptor subunit, IL-23R
-
Parham C, Chirica M, Timans J, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12 Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol. 2002;168(11):5699–5708.
-
(2002)
J Immunol
, vol.168
, Issue.11
, pp. 5699-5708
-
-
Parham, C.1
Chirica, M.2
Timans, J.3
-
20
-
-
0037449737
-
Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17
-
Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem. 2003;278(3):1910–1914.
-
(2003)
J Biol Chem
, vol.278
, Issue.3
, pp. 1910-1914
-
-
Aggarwal, S.1
Ghilardi, N.2
Xie, M.H.3
De Sauvage, F.J.4
Gurney, A.L.5
-
21
-
-
34548133583
-
Development, cytokine profile and function of human interleukin 17-producing helper T cells
-
Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol. 2007;8(9):950–957.
-
(2007)
Nat Immunol
, vol.8
, Issue.9
, pp. 950-957
-
-
Wilson, N.J.1
Boniface, K.2
Chan, J.R.3
-
22
-
-
79960776307
-
Interleukin-23: A key cytokine in inflammatory diseases
-
Duvallet E, Semerano L, Assier E, Falgarone G, Boissier MC. Interleukin-23: a key cytokine in inflammatory diseases. Ann Med. 2011;43(7):503–511.
-
(2011)
Ann Med
, vol.43
, Issue.7
, pp. 503-511
-
-
Duvallet, E.1
Semerano, L.2
Assier, E.3
Falgarone, G.4
Boissier, M.C.5
-
23
-
-
79958277385
-
IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease
-
Geremia A, Arancibia-Carcamo CV, Fleming MP, et al. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med. 2011;208(6):1127–1133.
-
(2011)
J Exp Med
, vol.208
, Issue.6
, pp. 1127-1133
-
-
Geremia, A.1
Arancibia-Carcamo, C.V.2
Fleming, M.P.3
-
24
-
-
79960209969
-
Therapeutic targeting of the IL-12/23 pathways: Generation and characterization of ustekinumab
-
Benson JM, Sachs CW, Treacy G, et al. Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab. Nat Biotechnol. 2011;29(7):615–624.
-
(2011)
Nat Biotechnol
, vol.29
, Issue.7
, pp. 615-624
-
-
Benson, J.M.1
Sachs, C.W.2
Treacy, G.3
-
25
-
-
0028861975
-
Antibodies to interleukin 12 abrogate established experimental colitis in mice
-
Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med. 1995;182(5):1281–1290.
-
(1995)
J Exp Med
, vol.182
, Issue.5
, pp. 1281-1290
-
-
Neurath, M.F.1
Fuss, I.2
Kelsall, B.L.3
Stuber, E.4
Strober, W.5
-
26
-
-
33747089041
-
Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology
-
Uhlig HH, McKenzie BS, Hue S, et al. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity. 2006;25(2):309–318.
-
(2006)
Immunity
, vol.25
, Issue.2
, pp. 309-318
-
-
Uhlig, H.H.1
McKenzie, B.S.2
Hue, S.3
-
27
-
-
33747777440
-
Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis
-
Becker C, Dornhoff H, Neufert C, et al. Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis. J Immunol. 2006;177(5):2760–2764.
-
(2006)
J Immunol
, vol.177
, Issue.5
, pp. 2760-2764
-
-
Becker, C.1
Dornhoff, H.2
Neufert, C.3
-
28
-
-
79955563439
-
Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases
-
Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1756–1767.
-
(2011)
Gastroenterology
, vol.140
, Issue.6
, pp. 1756-1767
-
-
Strober, W.1
Fuss, I.J.2
-
29
-
-
84901384833
-
Anti-IL-12/23 in Crohn’s disease: Bench and bedside
-
Niederreiter L, Adolph TE, Kaser A. Anti-IL-12/23 in Crohn’s disease: bench and bedside. Curr Drug Targets. 2013;14(12):1379–1384.
-
(2013)
Curr Drug Targets
, vol.14
, Issue.12
, pp. 1379-1384
-
-
Niederreiter, L.1
Adolph, T.E.2
Kaser, A.3
-
30
-
-
54249138516
-
Monoclonal antibody pharmacokinetics and pharmacodynamics
-
Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84(5):548–558.
-
(2008)
Clin Pharmacol Ther
, vol.84
, Issue.5
, pp. 548-558
-
-
Wang, W.1
Wang, E.Q.2
Balthasar, J.P.3
-
31
-
-
85080511101
-
-
US FDA Center for Drug Evaluation and Research: Ustekinumab, Accessed July 18, 2016
-
US FDA Center for Drug Evaluation and Research: Ustekinumab (2013). Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125261s086lbl.pdf. Accessed July 18, 2016.
-
(2013)
-
-
-
32
-
-
34249039292
-
A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis
-
Gottlieb AB, Cooper KD, McCormick TS, et al. A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Curr Med Res Opin. 2007;23(5):1081–1092.
-
(2007)
Curr Med Res Opin
, vol.23
, Issue.5
, pp. 1081-1092
-
-
Gottlieb, A.B.1
Cooper, K.D.2
McCormick, T.S.3
-
33
-
-
84858793037
-
Anti-TNF monoclonal antibodies in inflammatory bowel disease: Pharmacokinetics-based dosing paradigms
-
Ordas I, Mould DR, Feagan BG, Sandborn WJ. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther. 2012;91(4):635–646.
-
(2012)
Clin Pharmacol Ther
, vol.91
, Issue.4
, pp. 635-646
-
-
Ordas, I.1
Mould, D.R.2
Feagan, B.G.3
Sandborn, W.J.4
-
34
-
-
58849118867
-
Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis
-
Zhu Y, Hu C, Lu M, et al. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol. 2009;49(2):162–175.
-
(2009)
J Clin Pharmacol
, vol.49
, Issue.2
, pp. 162-175
-
-
Zhu, Y.1
Hu, C.2
Lu, M.3
-
35
-
-
69749119482
-
Risk-based strategy for the assessment of pharmacokinetic drug-drug interactions for therapeutic monoclonal antibodies
-
Zhou H, Davis HM. Risk-based strategy for the assessment of pharmacokinetic drug-drug interactions for therapeutic monoclonal antibodies. Drug Discov Today. 2009;14(17–18):891–898.
-
(2009)
Drug Discov Today
, vol.14
, Issue.17-18
, pp. 891-898
-
-
Zhou, H.1
Davis, H.M.2
-
36
-
-
74249094930
-
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis
-
Griffiths CE, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362(2):118–128.
-
(2010)
N Engl J Med
, vol.362
, Issue.2
, pp. 118-128
-
-
Griffiths, C.E.1
Strober, B.E.2
Van De Kerkhof, P.3
-
37
-
-
72049124819
-
Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn’s disease
-
Toedter GP, Blank M, Lang Y, Chen D, Sandborn WJ, de Villiers WJ. Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn’s disease. Am J Gastroenterol. 2009;104(11):2768–2773.
-
(2009)
Am J Gastroenterol
, vol.104
, Issue.11
, pp. 2768-2773
-
-
Toedter, G.P.1
Blank, M.2
Lang, Y.3
Chen, D.4
Sandborn, W.J.5
De Villiers, W.J.6
-
38
-
-
84995563335
-
Ustekinumab as Induction and Maintenance Therapy for Crohn’s disease
-
Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as Induction and Maintenance Therapy for Crohn’s disease. N Engl J Med. 2016. In Press.
-
(2016)
N Engl J Med
-
-
Feagan, B.G.1
Sandborn, W.J.2
Gasink, C.3
-
39
-
-
84984612711
-
O-001 A multicenter, double-blind, placebo-controlled phase 3 study of ustekinumab, a human IL-12/23P40 mAB, in moderate-service Crohn’s disease refractory to anti-TFNalpha: UNITI-1 (abstract)
-
Sandborn W, Gasink C, Blank M, et al. O-001 A multicenter, double-blind, placebo-controlled phase 3 study of ustekinumab, a human IL-12/23P40 mAB, in moderate-service Crohn’s disease refractory to anti-TFNalpha: UNITI-1 (abstract). Inflamm Bowel Dis. 2016;22(Suppl 1):S1.
-
(2016)
Inflamm Bowel Dis
, vol.22
-
-
Sandborn, W.1
Gasink, C.2
Blank, M.3
-
40
-
-
84976325622
-
OP054-LB4 A multicenter, double-blind, placebo-controlled Ph3 study of ustekinumab, a human monoclonal antibody to IL-12/23p40, in patients with moderately-severely active Crohn’s disease who are naïve or not refractory to anti-TNFa: UNITI-2 (abstract)
-
Feagan B, Gasink C, Lang Y, et al. OP054-LB4 A multicenter, double-blind, placebo-controlled Ph3 study of ustekinumab, a human monoclonal antibody to IL-12/23p40, in patients with moderately-severely active Crohn’s disease who are naïve or not refractory to anti-TNFa: UNITI-2 (abstract). United European Gastroenterol J. 2015;3(6):2.
-
(2015)
United European Gastroenterol J
, vol.3
, Issue.6
, pp. 2
-
-
Feagan, B.1
Gasink, C.2
Lang, Y.3
-
41
-
-
84992075713
-
768 A phase 3 randomized, multicenter, double-blind, placebo-controlled study of ustekinumab maintenance therapy in moderate-severe Crohn’s disease patients: Results from IM-UNITI (abstract)
-
Sandborn W, Feagan BG, Gasink C, et al. 768 A phase 3 randomized, multicenter, double-blind, placebo-controlled study of ustekinumab maintenance therapy in moderate-severe Crohn’s disease patients: results from IM-UNITI (abstract). Gastroenterology. 2016;150(4):S157–S158.
-
(2016)
Gastroenterology
, vol.150
, Issue.4
, pp. S157-S158
-
-
Sandborn, W.1
Feagan, B.G.2
Gasink, C.3
-
42
-
-
84995551580
-
Su1420 Ustekinumab treatment for Crohn’s disease in clinical practice: Experience at a tertiary medical center
-
Batista DD, Yadav S, Harmsen WS, et al. Su1420 Ustekinumab treatment for Crohn’s disease in clinical practice: experience at a tertiary medical center (abstract). Gastroenterology. 2014;146(5):S-464–S-465.
-
(2014)
Gastroenterology
, vol.146
, Issue.5
, pp. 464-465
-
-
Batista, D.D.1
Yadav, S.2
Harmsen, W.S.3
-
43
-
-
84927796919
-
Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn’s disease – the McGill experience
-
Kopylov U, Afif W, Cohen A, et al. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn’s disease – the McGill experience. J Crohns Colitis. 2014;8(11):1516–1522.
-
(2014)
J Crohns Colitis
, vol.8
, Issue.11
, pp. 1516-1522
-
-
Kopylov, U.1
Afif, W.2
Cohen, A.3
-
44
-
-
84958932029
-
Subcutaneous ustekinumab provides clinical benefit for two-thirds of patients with Crohn’s disease refractory to anti-tumor necrosis factor agents
-
Wils P, Bouhnik Y, Michetti P, et al. Subcutaneous ustekinumab provides clinical benefit for two-thirds of patients with Crohn’s disease refractory to anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol. 2016;14(2):242–250.e241–e242.
-
(2016)
Clin Gastroenterol Hepatol
, vol.14
, Issue.2
, pp. 242-250
-
-
Wils, P.1
Bouhnik, Y.2
Michetti, P.3
-
45
-
-
84976291747
-
Ustekinumab for the treatment of refractory Crohn’s disease: The Spanish experience in a large multicentre open-label cohort
-
Khorrami S, Ginard D, Marin-Jimenez I, et al. Ustekinumab for the treatment of refractory Crohn’s disease: the Spanish experience in a large multicentre open-label cohort. Inflamm Bowel Dis. 2016;22(7):1662–1669.
-
(2016)
Inflamm Bowel Dis
, vol.22
, Issue.7
, pp. 1662-1669
-
-
Khorrami, S.1
Ginard, D.2
Marin-Jimenez, I.3
-
46
-
-
84995667923
-
Pharmacokinetics and exposure-response relationships of intravenously administered ustekinumab during induction treatment in patients with Crohn’s disease: Results from the UNITI-1 and UNITI-2 studies (abstract)
-
Adedokun O, Xu Z, Gasink C, et al. Pharmacokinetics and exposure-response relationships of intravenously administered ustekinumab during induction treatment in patients with Crohn’s disease: results from the UNITI-1 and UNITI-2 studies (abstract). J Crohns Colitis. 2016;10:S23–S24.
-
(2016)
J Crohns Colitis
, vol.10
, pp. S23-S24
-
-
Adedokun, O.1
Xu, Z.2
Gasink, C.3
-
47
-
-
84995568401
-
Sa1934 Pharmacokinetics and exposure-response relationships of ustekinumab during IV induction and SC maintenance treatment of patients with Crohn’s disease with ustekinumab: Results from the UNITI-1, UNITI-2, and IM-UNITI studies (abstract)
-
Adedokun OJ, Xu Z, Gasink C, et al. Sa1934 Pharmacokinetics and exposure-response relationships of ustekinumab during IV induction and SC maintenance treatment of patients with Crohn’s disease with ustekinumab: results from the UNITI-1, UNITI-2, and IM-UNITI studies (abstract). Gastroenterology. 2016;150(4):S408.
-
(2016)
Gastroenterology
, vol.150
, Issue.4
-
-
Adedokun, O.J.1
Xu, Z.2
Gasink, C.3
-
48
-
-
85002578591
-
Association of ustekinumab trough concentrations with clinical, biochemical, and endoscopic outcomes (Abstract)
-
Battat R, Kopylov U, Bessissow T, et al. Association of ustekinumab trough concentrations with clinical, biochemical, and endoscopic outcomes (abstract). J Crohns Colitis. 2016;10:S74.
-
(2016)
J Crohns Colitis
, vol.10
-
-
Battat, R.1
Kopylov, U.2
Bessissow, T.3
-
49
-
-
33746534417
-
IL-23 promotes tumour incidence and growth
-
Langowski JL, Zhang X, Wu L, et al. IL-23 promotes tumour incidence and growth. Nature. 2006;442(7101):461–465.
-
(2006)
Nature
, vol.442
, Issue.7101
, pp. 461-465
-
-
Langowski, J.L.1
Zhang, X.2
Wu, L.3
-
50
-
-
0027239503
-
Antitumor and antimetastatic activity of interleukin 12 against murine tumors
-
Brunda MJ, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med. 1993;178(4):1223–1230.
-
(1993)
J Exp Med
, vol.178
, Issue.4
, pp. 1223-1230
-
-
Brunda, M.J.1
Luistro, L.2
Warrier, R.R.3
-
51
-
-
84881273940
-
Ustekinumab for the treatment of Crohn’s disease
-
Khanna R, Feagan BG. Ustekinumab for the treatment of Crohn’s disease. Immunotherapy. 2013;5(8):803–815.
-
(2013)
Immunotherapy
, vol.5
, Issue.8
, pp. 803-815
-
-
Khanna, R.1
Feagan, B.G.2
-
52
-
-
84875433817
-
Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: Final results from 5 years of follow-up
-
Papp KA, Griffiths CE, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013;168(4):844–854.
-
(2013)
Br J Dermatol
, vol.168
, Issue.4
, pp. 844-854
-
-
Papp, K.A.1
Griffiths, C.E.2
Gordon, K.3
-
53
-
-
84941599682
-
Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
-
Papp K, Gottlieb AB, Naldi L, et al. Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Drugs Dermatol. 2015;14(7):706–714.
-
(2015)
J Drugs Dermatol
, vol.14
, Issue.7
, pp. 706-714
-
-
Papp, K.1
Gottlieb, A.B.2
Naldi, L.3
-
54
-
-
13344284635
-
A reversible posterior leukoencephalopathy syndrome
-
Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334(8):494–500.
-
(1996)
N Engl J Med
, vol.334
, Issue.8
, pp. 494-500
-
-
Hinchey, J.1
Chaves, C.2
Appignani, B.3
-
55
-
-
80054734943
-
Reversible posterior leukoencephalopathy syndrome in a patient treated with ustekinumab: Case report and review of the literature
-
Gratton D, Szapary P, Goyal K, Fakharzadeh S, Germain V, Saltiel P. Reversible posterior leukoencephalopathy syndrome in a patient treated with ustekinumab: case report and review of the literature. Arch Dermatol. 2011;147(10):1197–1202.
-
(2011)
Arch Dermatol
, vol.147
, Issue.10
, pp. 1197-1202
-
-
Gratton, D.1
Szapary, P.2
Goyal, K.3
Fakharzadeh, S.4
Germain, V.5
Saltiel, P.6
-
56
-
-
84995633150
-
Mo1884 prevalence of inflammatory bowel disease among patients with psoriasis and incidence of serious infections in this subset: Results from the PSOLAR registry (abstract)
-
Loftus EV, Augustin M, Bissonnette R, et al. Mo1884 prevalence of inflammatory bowel disease among patients with psoriasis and incidence of serious infections in this subset: results from the PSOLAR registry (abstract). Gastroenterology. 2016;150(4):S805.
-
(2016)
Gastroenterology
, vol.150
, Issue.4
-
-
Loftus, E.V.1
Augustin, M.2
Bissonnette, R.3
-
57
-
-
80052074383
-
Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: A meta-analysis of randomized controlled trials
-
Ryan C, Leonardi CL, Krueger JG, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA. 2011;306(8):864–871.
-
(2011)
JAMA
, vol.306
, Issue.8
, pp. 864-871
-
-
Ryan, C.1
Leonardi, C.L.2
Krueger, J.G.3
-
58
-
-
84906790420
-
Demyelination in a patient receiving ustekinumab for refractory Crohn’s disease
-
Badat Y, Meissner WG, Laharie D. Demyelination in a patient receiving ustekinumab for refractory Crohn’s disease. J Crohns Colitis. 2014;8(9):1138–1139.
-
(2014)
J Crohns Colitis
, vol.8
, Issue.9
, pp. 1138-1139
-
-
Badat, Y.1
Meissner, W.G.2
Laharie, D.3
-
59
-
-
84964660329
-
Use of immunomodulators and biologics before, during, and after pregnancy
-
McConnell RA, Mahadevan U. Use of immunomodulators and biologics before, during, and after pregnancy. Inflamm Bowel Dis. 2016;22(1):213–223.
-
(2016)
Inflamm Bowel Dis
, vol.22
, Issue.1
, pp. 213-223
-
-
McConnell, R.A.1
Mahadevan, U.2
-
60
-
-
78650498507
-
Development in the cynomolgus macaque following administration of ustekinumab, a human anti-IL-12/23p40 monoclonal antibody, during pregnancy and lactation
-
Martin PL, Sachs C, Imai N, et al. Development in the cynomolgus macaque following administration of ustekinumab, a human anti-IL-12/23p40 monoclonal antibody, during pregnancy and lactation. Birth Defects Res B Dev Reprod Toxicol. 2010;89(5):351–363.
-
(2010)
Birth Defects Res B Dev Reprod Toxicol
, vol.89
, Issue.5
, pp. 351-363
-
-
Martin, P.L.1
Sachs, C.2
Imai, N.3
-
61
-
-
84977162841
-
Pregnancy outcomes in women exposed to ustekinumab in the psoriasis clinical development program
-
Schaufelberg BW, Horn E, Cather J, Rahawi K. Pregnancy outcomes in women exposed to ustekinumab in the psoriasis clinical development program (abstract). J Am Acad Dermatol. 2014;70(5):AB178.
-
(2014)
J am Acad Dermatol
, vol.70
, Issue.5
-
-
Schaufelberg, B.W.1
Horn, E.2
Cather, J.3
Rahawi, K.4
-
62
-
-
84995668306
-
437 Do infant serum levels of biologic agents at birth correlate with risk of adverse outcomes? Results from the PIANO registry
-
Mahadevan U, Martin C, Kane SV, Dubinsky M, Sands BE, Sandborn W. 437 Do infant serum levels of biologic agents at birth correlate with risk of adverse outcomes? Results from the PIANO registry (abstract). Gastroenterology. 2016;150(4):S91–S92.
-
(2016)
Gastroenterology
, vol.150
, Issue.4
, pp. S91-S92
-
-
Mahadevan, U.1
Martin, C.2
Kane, S.V.3
Dubinsky, M.4
Sands, B.E.5
Sandborn, W.6
-
63
-
-
84959220441
-
The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy
-
Nguyen GC, Seow CH, Maxwell C, et al. The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy. Gastroenterology. 2016;150(3):734–757.e731.
-
(2016)
Gastroenterology
, vol.150
, Issue.3
, pp. 734-757
-
-
Nguyen, G.C.1
Seow, C.H.2
Maxwell, C.3
-
64
-
-
84941887963
-
Update on the medical management of Crohn’s disease
-
Deepak P, Bruining DH. Update on the medical management of Crohn’s disease. Curr Gastroenterol Rep. 2015;17(11):41.
-
(2015)
Curr Gastroenterol Rep
, vol.17
, Issue.11
, pp. 41
-
-
Deepak, P.1
Bruining, D.H.2
-
65
-
-
84888221077
-
American gastroenterological association institute guideline on the use of thiopurines, methotrexate, and anti-TNF-alpha biologic drugs for the induction and maintenance of remission in inflammatory Crohn’s disease
-
Terdiman JP, Gruss CB, Heidelbaugh JJ, Sultan S, Falck-Ytter YT. American gastroenterological association institute guideline on the use of thiopurines, methotrexate, and anti-TNF-alpha biologic drugs for the induction and maintenance of remission in inflammatory Crohn’s disease. Gastroenterology. 2013;145(6):1459–1463.
-
(2013)
Gastroenterology
, vol.145
, Issue.6
, pp. 1459-1463
-
-
Terdiman, J.P.1
Gruss, C.B.2
Heidelbaugh, J.J.3
Sultan, S.4
Falck-Ytter, Y.T.5
-
66
-
-
84951906995
-
Systematic review: Predicting and optimising response to anti-TNF therapy in Crohn’s disease – algorithm for practical management
-
Ding NS, Hart A, De Cruz P. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn’s disease – algorithm for practical management. Aliment Pharmacol Ther. 2016;43(1):30–51.
-
(2016)
Aliment Pharmacol Ther
, vol.43
, Issue.1
, pp. 30-51
-
-
Ding, N.S.1
Hart, A.2
De Cruz, P.3
-
67
-
-
79953688705
-
Review article: Loss of response to anti-TNF treatments in Crohn’s disease
-
Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn’s disease. Aliment Pharmacol Ther. 2011;33(9):987–995.
-
(2011)
Aliment Pharmacol Ther
, vol.33
, Issue.9
, pp. 987-995
-
-
Ben-Horin, S.1
Chowers, Y.2
-
68
-
-
79953786419
-
Loss of response and need for adalimumab dose intensification in Crohn’s disease: A systematic review
-
Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn’s disease: a systematic review. Am J Gastroenterol. 2011;106(4):674–684.
-
(2011)
Am J Gastroenterol
, vol.106
, Issue.4
, pp. 674-684
-
-
Billioud, V.1
Sandborn, W.J.2
Peyrin-Biroulet, L.3
-
69
-
-
84906569062
-
Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed
-
Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147(3):618–627.e613.
-
(2014)
Gastroenterology
, vol.147
, Issue.3
, pp. 618-627
-
-
Sands, B.E.1
Feagan, B.G.2
Rutgeerts, P.3
-
70
-
-
84882749768
-
Vedolizumab as induction and maintenance therapy for Crohn’s disease
-
Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369(8):711–721.
-
(2013)
N Engl J Med
, vol.369
, Issue.8
, pp. 711-721
-
-
Sandborn, W.J.1
Feagan, B.G.2
Rutgeerts, P.3
-
72
-
-
84943663241
-
Review article: Pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases
-
Papamichael K, Van Stappen T, Jairath V, et al. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases. Aliment Pharmacol Ther. 2015;42(10):1158–1169.
-
(2015)
Aliment Pharmacol Ther
, vol.42
, Issue.10
, pp. 1158-1169
-
-
Papamichael, K.1
Van Stappen, T.2
Jairath, V.3
-
73
-
-
84895424744
-
Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-gamma-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment
-
Tillack C, Ehmann LM, Friedrich M, et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-gamma-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut. 2014;63(4):567–577.
-
(2014)
Gut
, vol.63
, Issue.4
, pp. 567-577
-
-
Tillack, C.1
Ehmann, L.M.2
Friedrich, M.3
-
74
-
-
84939266240
-
Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: A 14-year experience
-
Freling E, Baumann C, Cuny JF, et al. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience. Am J Gastroenterol. 2015;110(8):1186–1196.
-
(2015)
Am J Gastroenterol
, vol.110
, Issue.8
, pp. 1186-1196
-
-
Freling, E.1
Baumann, C.2
Cuny, J.F.3
-
75
-
-
84962288522
-
Incidence, clinical characteristics, and management of psoriasis induced by anti-TNF therapy in patients with inflammatory bowel disease: A nationwide cohort study
-
Guerra I, Perez-Jeldres T, Iborra M, et al. Incidence, clinical characteristics, and management of psoriasis induced by anti-TNF therapy in patients with inflammatory bowel disease: a nationwide cohort study. Inflamm Bowel Dis. 2016;22(4):894–901.
-
(2016)
Inflamm Bowel Dis
, vol.22
, Issue.4
, pp. 894-901
-
-
Guerra, I.1
Perez-Jeldres, T.2
Iborra, M.3
-
76
-
-
84862309480
-
Ustekinumab for peristomal pyoderma gangrenosum
-
Fahmy M, Ramamoorthy S, Hata T, Sandborn WJ. Ustekinumab for peristomal pyoderma gangrenosum. Am J Gastroenterol. 2012;107(5):794–795.
-
(2012)
Am J Gastroenterol
, vol.107
, Issue.5
, pp. 794-795
-
-
Fahmy, M.1
Ramamoorthy, S.2
Hata, T.3
Sandborn, W.J.4
-
77
-
-
84872683372
-
Severely recalcitrant pyoderma gangrenosum successfully treated with ustekinumab
-
Goldminz AM, Botto NC, Gottlieb AB. Severely recalcitrant pyoderma gangrenosum successfully treated with ustekinumab. J Am Acad Dermatol. 2012;67(5):e237–e238.
-
(2012)
J am Acad Dermatol
, vol.67
, Issue.5
-
-
Goldminz, A.M.1
Botto, N.C.2
Gottlieb, A.B.3
-
78
-
-
80054754826
-
Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab
-
Guenova E, Teske A, Fehrenbacher B, et al. Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab. Arch Dermatol. 2011;147(10):1203–1205.
-
(2011)
Arch Dermatol
, vol.147
, Issue.10
, pp. 1203-1205
-
-
Guenova, E.1
Teske, A.2
Fehrenbacher, B.3
-
79
-
-
84902378517
-
Involvement of IL-23 in enteropathic arthritis patients with inflammatory bowel disease: Preliminary results
-
Gheita TA, El G II, El-Fishawy HS, Aboul-Ezz MA, Kenawy SA. Involvement of IL-23 in enteropathic arthritis patients with inflammatory bowel disease: preliminary results. Clin Rheumatol. 2014;33(5):713–717.
-
(2014)
Clin Rheumatol
, vol.33
, Issue.5
, pp. 713-717
-
-
Gheita, T.A.1
El, G.2
El-Fishawy, H.S.3
Aboul-Ezz, M.A.4
Kenawy, S.A.5
-
80
-
-
84894082076
-
Specific targeting of interleukin-23p19 as effective treatment for psoriasis
-
Levin AA, Gottlieb AB. Specific targeting of interleukin-23p19 as effective treatment for psoriasis. J Am Acad Dermatol. 2014;70(3):555–561.
-
(2014)
J am Acad Dermatol
, vol.70
, Issue.3
, pp. 555-561
-
-
Levin, A.A.1
Gottlieb, A.B.2
-
81
-
-
84961792836
-
A review of biologic therapies targeting IL-23 and IL-17 for use in moderate-to-severe plaque psoriasis
-
Campa M, Mansouri B, Warren R, Menter A. A review of biologic therapies targeting IL-23 and IL-17 for use in moderate-to-severe plaque psoriasis. Dermatol Ther. 2016;6(1):1–12.
-
(2016)
Dermatol Ther
, vol.6
, Issue.1
, pp. 1-12
-
-
Campa, M.1
Mansouri, B.2
Warren, R.3
Menter, A.4
-
83
-
-
84991675498
-
Efficacy and safety of different dose regimens of a selective IL-23p19 inhibitor (BI 655066) compared with ustekinumab in patients with moderate-to-severe plaque psoriasis with and without psoriatic arthritis
-
Accessed October 9, 2016
-
Papp K, Menter A, Sofen H, et al. Efficacy and safety of different dose regimens of a selective IL-23p19 inhibitor (BI 655066) compared with ustekinumab in patients with moderate-to-severe plaque psoriasis with and without psoriatic arthritis (abstract). Arthritis Rheumatol. 2015;67(Suppl 10). Available from: http://acrabstracts.org/abstract/efficacy-and-safety-of-different-dose-regimens-of-a-selective-il-23p19-inhibitor-bi-655066-compared-with-ustekinumab-in-patients-with-moderate-to-severe-plaque-psoriasis-with-and-without-psoriatic-a/. Accessed October 9, 2016.
-
(2015)
Arthritis Rheumatol
-
-
Papp, K.1
Menter, A.2
Sofen, H.3
-
84
-
-
85080504806
-
-
Janssen Research & Development, LLC, Bethesda (MD): National Library of Medicine (US), cited 2016 Oct 7NLMIdentifier: NCT02203032, Accessed October 7, 2016
-
Janssen Research & Development, LLC. A study of guselkumab in participants with moderate to severe plaque-type psoriasis and an inadequate response to ustekinumab (NAVIGATE). Bethesda (MD): National Library of Medicine (US); 2000 [cited 2016 Oct 7]. NLM Identifier: NCT02203032. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02203032. Accessed October 7, 2016.
-
(2000)
A Study of Guselkumab in Participants with Moderate to Severe Plaque-Type Psoriasis and an Inadequate Response to Ustekinumab (NAVIGATE)
-
-
-
85
-
-
84995682586
-
830 Initial evaluation of MEDI2070 (Specific anti-IL-23 antibody) in patients with active Crohn’s disease who have failed anti-TNF antibody therapy: A randomized, double-blind placebo-controlled phase 2A induction study
-
Sands BE, Chen J, Penney M, et al. 830 Initial evaluation of MEDI2070 (specific anti-IL-23 antibody) in patients with active Crohn’s disease who have failed anti-TNF antibody therapy: a randomized, double-blind placebo-controlled phase 2A induction study (abstract). Gastroenterology. 2015;148(4):S-163–S-164.
-
(2015)
Gastroenterology
, vol.148
, Issue.4
, pp. 163-164
-
-
Sands, B.E.1
Chen, J.2
Penney, M.3
-
86
-
-
84995691457
-
812a Efficacy and safety of induction therapy with the selective IL-23 inhibitor BI 655066, in patients with moderate-to-severe Crohn’s disease: Results of a randomized, double-blind, placebo-controlled phase II study
-
Feagan BG, Sandborn W, Panés J, et al. 812a Efficacy and safety of induction therapy with the selective IL-23 inhibitor BI 655066, in patients with moderate-to-severe Crohn’s disease: results of a randomized, double-blind, placebo-controlled phase II study (abstract). Gastroenterology. 2016;150(4):S1266.
-
(2016)
Gastroenterology
, vol.150
, Issue.4
-
-
Feagan, B.G.1
Sandborn, W.2
Panés, J.3
-
87
-
-
84995682599
-
-
Sun Pharma and Merck & Co. Inc, Merck & Co., Inc. [press release]. Merck Sharp & Dohme Corp. websiteSeptember 17, Accessed October 7, 2016
-
Sun Pharma and Merck & Co. Inc. Enter into Licensing Agreement for Tildrakizumab, Merck & Co., Inc. [press release]. Merck Sharp & Dohme Corp. website; 2014 [September 17]. Available from: http://www.merck.com/licensing/our-partnership/sunpharma_partnership.html. Accessed October 7, 2016.
-
Enter into Licensing Agreement for Tildrakizumab
-
-
-
88
-
-
84978399780
-
The present and future of inflammatory bowel disease treatment
-
Sandborn WJ. The present and future of inflammatory bowel disease treatment. Gastroenterol Hepatol. 2016;12(7):438–441.
-
(2016)
Gastroenterol Hepatol
, vol.12
, Issue.7
, pp. 438-441
-
-
Sandborn, W.J.1
-
89
-
-
84995595066
-
Serum soluble IL2-receptor is increased in a subpopulation of Crohns disease patients, who respond to open label use of ustekinumab, a human monoclonal antibody to IL-12/23p40
-
Kuehbacher T, Nikolaus S, Schreiber S. Serum soluble IL2-receptor is increased in a subpopulation of Crohns disease patients, who respond to open label use of ustekinumab, a human monoclonal antibody to IL-12/23p40 (abstract). Gastroenterology. 2011;140(5):S-589.
-
(2011)
Gastroenterology
, vol.140
, Issue.5
-
-
Kuehbacher, T.1
Nikolaus, S.2
Schreiber, S.3
|